Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials.

Oncotarget · 2017 · PMC5641210 · PMID 29069867

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Significantly, PFS improvement in doublets in EGFR wild-type ( p < 0.0001), KRAS mutant ( p < 0.00001), KRAS wild-type ( p = 0.03) was observed; While, PFS in EGFR -mutant patients showed a trend in favor of single-agent erlotinib (HR 1.09, 95%CI 0.63-1.88).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.